Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

PerkinElmer (NY: PKI )

135.17 USD +2.39 (+1.80%)
Streaming Delayed Price Updated: 10:22 AM EDT, Apr 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about PerkinElmer

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for... 
From Business Wire News Releases
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference
Horizon Discovery, A PerkinElmer, Inc. Company Expands Gene Modulation Portfolio With Industry First CRISPRi Reagents 
From Business Wire News Releases
PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX®... 
From Business Wire News Releases
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec... 
From Business Wire News Releases
PerkinElmer Prices Offering of Senior Notes
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $400.0 million aggregate principal amount of 2.550%... 
From Business Wire News Releases
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test... 
From PR Newswire
PerkinElmer to Present at Barclays Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Barclays Global Healthcare Conference on Wednesday,... 
From Business Wire News Releases
PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening
PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or... 
From Business Wire News Releases
PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process. The VBL... 
From Business Wire News Releases
PerkinElmer to Present at Cowen Health Care Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on Monday,... 
From Business Wire News Releases
Organogenesis Appoints David C. Francisco as Chief Financial Officer
From GlobeNewswire News Releases
OXFORD IMMUNOTEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to... 
From PR Newswire
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021. 
From Business Wire News Releases
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021. This dividend is payable on May 7, 2021 to all... 
From Business Wire News Releases
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Oxford Immunotec Global PLC Buyout
From GlobeNewswire News Releases
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA)... 
From Business Wire News Releases
OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to... 
From Business Wire News Releases
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%,... 
From Business Wire News Releases
PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under... 
From Business Wire News Releases
PerkinElmer to Present at J.P. Morgan Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Monday,... 
From Business Wire News Releases
PerkinElmer to Host Virtual Life Science Event
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a Virtual Life Science Event for the investment community on... 
From Business Wire News Releases
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five... 
From Business Wire News Releases
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA... 
From Business Wire News Releases
PerkinElmer to Present at Wolfe Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday,... 
From Business Wire News Releases
PerkinElmer to Present at Stifel Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday,... 
From Business Wire News Releases
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million). 
From Business Wire News Releases
PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus... 
From Business Wire News Releases
PerkinElmer Announces Financial Results for the Third Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020. 
From Business Wire News Releases
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries... 
From Business Wire News Releases
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to all... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.